Objective To summarize the relationship between microRNA and the occurrence and progression of colorectal cancer， and to investigate the application value of microRNA in the diagnosis， treatment， and prognosis evaluation of colorectal cancer. Methods Domestic and international publications involving the relationship between microRNA and colorectal cancer were retrieved and reviewed. Results MicroRNA acted as an oncogene or tumor suppressor gene to participate in cell proliferation， differentiation， apoptosis， metabolism， tumor genesis， and tumor progression. The abnormal expression of microRNA was closely related to the occurrence and progression of colorectal cancer. As specific biomarker， microRNA could be applied in early diagnosis， chemotherapy strategy-making， and prognostic evaluation of colorectal cancer. Conclusion MicroRNA is definitely related to the occurrence and progression of colorectal cancer， and it has great prospect in the basic research and clinical applications of colorectal cancer.
ObjectiveTo summarize the definitions, risk factors, and preoperative evaluation methods of posthe-patectomy liver failure. MethodsDomestic and international publications involving posthepatectomy liver failure were retrieved and reviewed. ResultsThere was no uniform definition of posthepatectomy liver failure, however, the most approbatory definitions were "50-50 criteria" and "International Study Group of Liver Surgery (ISGLS) criteria". Risk factors of posthepatectomy liver failure included patient-related factors, liver-related factors, and surgery-related factors, and preoperative evaluation was mainly based on liver function and liver volume. ConclusionPosthepatectomy liver failure is the main cause of postoperative death, sufficient preoperative evaluation and effective measures to decrease intraoperative blood loss and shorten surgery duration are helpful to prevent and (or) reduce posthepatectomy liver failure.
Evidence from numerous animal models and clinical studies in recent years has demonstrated that macrophages play an important role in the regulation of liver fibrosis regression. The safety and efficacy of utilizing autologous macrophages for the treatment of liver fibrosis have been demonstrated in patients and shows promising application prospects, but the therapeutic effects need to be improved. Cirrhotic liver undergoes a process of marked extracellular matrix degradation after partial hepatectomy surgery, and single-cell sequencing identified multiple restorative macrophage subsets that express different matrix metalloproteinases (MMPs) at high levels. Future efforts to further characterize this population of macrophages and improve their enrichment in the liver may allow macrophage therapy to be a highly effective strategy to reverse liver fibrosis.
ObjectiveTo understand the latest epidemiological situation of liver cancer worldwide and in China. MethodsThis team organized and briefly interpreted the results of the two reports, the International Agency for Research on Cancer team released the latest global cancer statistics report in its authoritative journal, CA: A Cancer Journal for Clinicians, in April 2024, the research team from the National Center for Chronic and Noncommunicable Disease Control and Prevention at the Chinese Center for Disease Control and Prevention published an article in the Lancet Public Health on the changes in cancer burden in China from 2005 to 2020. The epidemiological trends of liver cancer worldwide and in China from 2018 to 2022, the changes in age-standardized incidencerate by world standard population (ASIRW) and age-standardized mortality rate by world standard population (ASMRW) of liver cancer in countries with different human development index (HDI) and income levels in the world in 2022, the incidence and death of liver cancer in different age groups in the world and China in 2022, and the changes in the disease burden of liver cancer in China from 2005 to 2020 were anlyzed. ResultsIn 2022, there were 865 269 new cases and 757 948 deaths of liver cancer globally, it was the sixth most common malignancy and the third leading cause of cancer-related deaths worldwide. The incidence and mortality of liver cancer worldwide and in China from 2018 to 2022 tended to be stable or declining, which in men were higher than those in women, and which in all population and males in China were higher than those in the world. The ASIRW and ASMRW were the highest in the countries with high HDI and upper-middle income levels. With the increase of age, the ASIRW and ASMRW of liver cancer continued to increase in the world and in China. The average annual percentage changes (AAPCs) in the deaths, ASMRW, year of life loss, and age-standardized year of life loss for all age groups in China from 2005 to 2020 were negative, indicating a downward trend for each of these indicators. The ASMRW of liver cancer increased with the increasing of age in 2020 in China. ConclusionsLiver cancer continues to pose a significant disease burden worldwide and in China. Therefore, implementing primary and secondary prevention strategies for liver cancer in the future is a major measure for its prevention and control. Additionally, continuous efforts are needed to ensure multidisciplinary and standardized management of liver cancer throughout its course.
To challenge the 15% enhancement of 5-year survival of cancer for the plan of “Health-China 2030”, we must strive the following measurements to complete the 15% enhancement of 5-year survival of liver cancer: conduct conversion therapy and conversion to resectability for the 70% of unresectable intermediate-to-advanced stage liver cancer so as to prolong survival; try our best to identify and treat the people of HBV and HCV infection, and to screen the risk people so as to reduce the incidence of liver cancer and the proportion for intermediate-to-advanced stage liver cancer; continue to try our best in the full course management of liver cancer under the frame of MDT.
To address the persistent challenges in surgical clinical research, we provide a comprehensive analysis of the series of articles on randomized controlled trials (RCTs) methodology guidance published in JAMA Surgery from 2022 to 2023. This section contents focus on critical aspects of RCTs, including trial design, selection criteria, ethical considerations, quality control, and budgeting and funding support. The objective is to enhance the understanding of RCTs among researchers, particularly surgeons, thereby guiding them in conducting high-quality and scientifically robust RCTs.
Objective To explore the factors associated with clinic follow-up of old patients with colorectal cancer and provide more evidence to improve the efficiency and quality of clinic follow-up after sugery. Methods The data of 253 patients who were underwent sugery because of old colorectal cancer in our hospital from January 2009 to May 2010 were reviewed. Data about the rate and times of clinic follow-up within 6 months after operation were collected via Hospital Information Systerm, then the follow-up rate was calculated, and to analyse the possible factors associated with follow-up times and rate. Results The total follow-up rate was 84.2%（213/253）, and the total times of follow-up was between 0 to 24 times per one, （4.08±0.03）times on average. On the times of follow-up, patients inside the city was higher than that outside, patients with medical or postoperative complications were higher than those without, and patients with a stoma was lower than that without, and the differences were statistically significant （P＜0.05）.While on the follow-up rate, patients underwent a radical sugery or with a stoma were lower than those not or without, and the differences were statistically significant （P＜0.05）. Conclusions The clinic follow-up of old colorectal cancer patients is not satisfactory, and the possible factors associated with follow-up times or rate are the distance between residence and hospital, have medical complications or not, have postoperative complications or not, radical sugery or not, and with a stoma or without.
ObjectiveTo quantitate expression of miR21 in rectal cancer of different tumor stages and discuss their significances. MethodThe expression of miR21 was detected and quantitated in the rectal cancer tissues and corresponding adjacent normal tissues of 40 patients with rectal cancer in this hospital from August 2012 to October 2012 by Taq Man microRNA assay. ResultsThe significant overexpression of miR21 was observed in the rectal cancer tissues (4.122±1.973 versus 1.825±0.661, P=0.000)as compared with the corresponding adjacent normal tissues. The expressions of miR21 in the rectal cancer tissues of N1-N2 and Dukes C-D stages were significantly higher than those in the rectal cancer tissues of N0(4.852±2.344 versus 3.391±1.171, P=0.019)and Dukes A-B stage(4.787±2.304 versus 3.386±1.203, P=0.021). From N0 to N2 stage, the expression of miR21 increased progressively in the rectal cancer, and the expression in the rectal cancer tissues of N2 stage was significantly higher than that in the N0 stage(5.556±1.500 versus 3.391±1.171, P=0.010). And receiver operating characteristics curve analysis showed that miR21 could discriminate N 0 stage from N1-N2 stage with a 0.698 area under curve(AUC), 50.0% sensitivity and 90.0% specificity, Dukes C-D stage from A-B stage with a 0.689 AUC, 42.9% sensitivity and 94.7% specificity. ConclusionmiR21 appears to have a potential correlation with N and Dukes stages of rectal cancer, which cautiously and optimistically suggests that it could be a potential novel biomarker for predicting tumor stage preoperatively.